查看购物车
  • Traditional Chinese
  • English
抗生素和抗真菌药物市场规模和预测、全球和区域份额、趋势和成长机会分析报告范围：按药物类别、适应症、给药途径、配销通路和地理位置
市场调查报告书
商品编码
1591395

抗生素和抗真菌药物市场规模和预测、全球和区域份额、趋势和成长机会分析报告范围：按药物类别、适应症、给药途径、配销通路和地理位置

Antibiotics and Antimycotics Market Size and Forecast, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Drug Class, Indication, Route of Administration, Distribution Channel, and Geography
出版日期: | 出版商: The Insight Partners | 英文 203 Pages | 订单完成后即时交付

价格

全球抗生素和抗真菌药物市场预计将从2023年的612亿美元成长到2031年的915.4亿美元；预计 2023 年至 2031 年复合年增长率为 5.2%。抗生素和抗真菌药物市场的成长归因于老年人口的增加、牙科疾病负担的增加以及美容牙科需求的激增。

抗生素和抗真菌药物是针对不同类型病原体的抗菌剂。抗生素进一步分为杀菌抗生素（青霉素类和头孢菌素类）和抑菌抗生素（四环素类和大环内酯类），前者可杀死细菌，后者抑制细菌生长。抗生素被广泛用于治疗细菌感染，但其有效性受到抗生素抗药性菌株的增加的挑战。抗真菌药物是专门为对抗真菌感染而设计的。它们透过针对真菌细胞结构或代谢的各个方面发挥作用。常见的抗霉菌药物包括唑类（氟康唑）、多烯类（两性霉素 B）和棘白菌素类（卡泊芬净）。抗真菌药物对于治疗念珠菌病和曲霉病等真菌引起的疾病至关重要。

北美抗生素和抗真菌药物市场分为美国、加拿大和墨西哥。该市场的主要推动力是细菌和真菌感染盛行率的上升、医疗保健基础设施的发展以及用于治疗此类感染的各种抗生素和抗真菌药物的可用性。此外，主要参与者产品发布、批准和其他策略倡议的增加预计将为预测期内的市场成长创造机会。

在北美，美国是抗生素和抗真菌药物的最大市场。美国抗生素和抗真菌药物市场的成长是由真菌和细菌感染的日益流行以及对有效治疗方案的不断增长的需求所推动的。肺炎是美国最常见的呼吸道感染。根据 Verywell Health Journal 2024 报告，美国每年约有 150 万成年人被诊断出患有肺炎；其中约 100 万人入院，5 万人因肺炎或相关併发症死亡。阿莫西林和阿奇霉素是美国门诊最常使用的治疗细菌感染的抗生素。此外，随着药物研究和技术的不断进步，新型抗生素和抗真菌药物的开发势头强劲，回应了人们对抗生素抗药性日益增长的担忧和对创新疗法的需求。此外，人们越来越认识到抗菌药物管理计划的重要性，这导致人们对抗生素处方采取更谨慎的态度，从而促使人们转向标靶治疗和联合治疗。这在医院环境中尤其明显，医院获得性感染发生率不断上升，因此需要使用强效抗菌药物。

主要参与者正在采取产品发布、产品批准和合作等策略性倡议，预计将在预测期内支持市场成长。例如，2024年4月，美国食品药物管理局（FDA）核准Zevtera（注射头孢比普罗美多卡利钠）用于治疗成人金黄色葡萄球菌血流感染（SAB），包括右侧感染性心内膜炎和成人患有急性细菌性皮肤和皮肤结构感染（ABSSSI）。此外，2023年3月，美国FDA批准REZZAYO（注射用瑞扎芬净）用于治疗念珠菌血症和侵袭性念珠菌症。

产品开发和治疗提供方法的技术进步

製药业强调将深度学习、人工智慧（AI）和机器学习等智慧技术融入新型抗生素的开发中。研究人员正在努力建立用于识别新活性化合物的工具和平台。利用新技术发现新抗生素的能力预计将改变抗生素和抗真菌药物开发和审批流程的整体过程。

开发针对革兰氏阴性菌的抗生素给研究人员带来了巨大的挑战，许多药物仍处于开发阶段。由于营养特异性蛋白质通道（孔蛋白），这些细菌包膜的渗透性有限，限制了非必需分子（包括抗生素）跨膜的移动。考虑到细胞膜渗透性的困难，研究人员开发了一种新的计算抗生素筛选平台（CLASP），可根据孔蛋白的分析来帮助识别潜在的药物分子。粗粒度 (CG) 解析度、先进的采样技术和平行运算环境等优势可最大限度地提高 CLASP 的效能。该平台可在几个小时内为正在研究的潜在药物分子提供完整的热力学和动力学结果。它还有助于理解或识别产生结构-性质关係的小分子库，以发现具有高渗透性的抗生素。

人们越来越倾向于精准医疗方法，包括根据患者的基因谱和大量人群中常见的抗药性模式来调整抗生素治疗。这样的革命将改善药物的功能，同时确保最小的副作用并遏制抗药性的发展。噬菌体疗法已成为另一种新方法，涉及传统微生物治疗与噬菌体的潜在组合，以靶向并消灭抗生素抗性病原体。基因编辑技术（例如 CRISPR）的最新进展有望进一步增强噬菌体疗法的前景。因此，药物开发和治疗方法的技术进步预计将在未来几年为抗生素和抗真菌药物市场的成长带来新的成长趋势。

抗生素和抗真菌药物市场：竞争格局和主要发展

辉瑞公司、诺华公司、赛诺菲公司、罗氏公司、默克公司、葛兰素史克公司、强生公司、西普拉有限公司、拜耳公司、艾伯维公司和安斯泰来製药公司都是在该地区运营的主要公司。

美国食品药物管理局、美国国立卫生研究院、联合国国际儿童紧急基金会（UNICEF）、世界卫生组织（WHO）、国家法定疾病监测系统是准备抗生素和抗真菌药物市场时参考的主要和次要来源报告。

目录

第 1 章：简介

第 2 章：执行摘要

  • 主要见解

第 3 章：研究方法

  • 二次研究
  • 初步研究
    • 假设表述：
    • 宏观经济因素分析：
    • 显影基数：
    • 数据三角测量：
    • 国家级资料：

第 4 章：抗生素和抗霉菌药物市场格局

  • 概述
  • PEST分析

第 5 章：抗生素和抗真菌药物市场 - 主要市场动态

  • 抗生素和抗真菌药物市场 - 主要市场动态
  • 市场驱动因素：
    • 传染病病率增加
    • 人们对真菌感染的认识不断增强
  • 市场限制
    • 抗菌素抗药性、财务障碍和广泛的监管流程
  • 市场机会
    • 持续的资助和研发计划
  • 未来趋势
    • 产品开发和治疗提供方法的技术进步
  • 驱动因素和限制的影响：

第 6 章：抗生素和抗真菌药物市场 - 全球市场分析

  • 抗生素和抗真菌药物市场收入，2021-2031
  • 抗生素和抗真菌药物市场预测分析

第 7 章：抗生素和抗真菌药物市场分析 - 按药物类别

  • 青霉素
  • 头孢菌素类
  • 碳青霉烯类
  • 大环内酯类
  • 氨基糖苷类
  • 奎诺酮类
  • 磺胺类药物
  • 四环素类
  • 唑类
  • 其他的

第 8 章：抗生素和抗真菌药物市场分析 - 按适应症

  • 皮肤感染
  • 呼吸道感染
  • 泌尿道感染（UTI）
  • 败血症
  • 耳朵感染
  • 胃肠道感染
  • 其他的

第 9 章：抗生素和抗真菌药物市场分析 - 按给药途径

  • 口服
  • 专题
  • 其他的

第 10 章：抗生素和抗真菌药物市场分析 - 按配销通路

  • 医院药房
  • 零售药局
  • 网路药局

第 11 章：抗生素和抗真菌药物市场 - 地理分析

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 法国
    • 西班牙
    • 义大利
    • 英国
    • 欧洲其他地区
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 韩国
    • 亚太地区其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 南非
    • 阿拉伯聯合大公国
    • 中东和非洲其他地区
  • 南美洲和中美洲
    • 巴西
    • 阿根廷
    • 南美洲和中美洲其他地区

第 12 章：抗生素和抗真菌药物市场 - 产业格局

  • 概述
  • 抗生素和抗真菌药物市场的成长策略
  • 有机成长策略
    • 概述
  • 无机成长策略
    • 概述

第 13 章：公司简介

  • Pfizer Inc
  • Novartis AG
  • Sanofi SA
  • F. Hoffmann-La Roche Ltd
  • Merck & Co Inc
  • GSK Plc
  • Johnson & Johnson
  • Cipla Ltd
  • Bayer AG
  • AbbVie Inc
  • Astellas Pharma Inc

第 14 章：附录

Product Code: TIPRE00021878

The global antibiotics and antimycotics market is anticipated to grow from US$ 61.20 billion in 2023 and is projected to reach US$ 91.54 billion by 2031; it is expected to register a CAGR of 5.2% during 2023-2031. The antibiotics and antimycotics market growth is attributed to the increasing geriatric population, the growing burden of dental diseases, and the surging demand for cosmetic dentistry.

Antibiotics and antimycotics are antimicrobial agents targeting different types of pathogens. Antibiotics are further classified into bactericidal antibiotics, which kill bacteria (penicillins and cephalosporins), and bacteriostatic antibiotics, which inhibit bacterial growth (tetracyclines and macrolides). Antibiotics are widely used to treat bacterial infections, but their effectiveness is challenged by the rise of antibiotic-resistant strains. Antimycotics are specifically designed to combat fungal infections. They work by targeting various aspects of fungal cell structure or metabolism. Common classes of antimycotics include azoles (fluconazole), polyenes (amphotericin B), and echinocandins (caspofungin). Antimycotics are essential in treating conditions caused by fungi, such as candidiasis and aspergillosis.

The North America antibiotics and antimycotics market is segmented into the US, Canada, and Mexico. The market is mainly driven by the rising prevalence of bacterial and fungal infections, the presence of developed healthcare infrastructure, and the availability of a wide range of antibiotics and antimycotics for the treatment of such infections. Additionally, the rise in product launches, approvals, and other strategic initiatives by major players is expected to create opportunities for the market growth during the forecast period.

In North America, the US is the largest market for antibiotics and antimycotics. The US antibiotics and antimycotics market growth is driven by the increasing prevalence of fungal and bacterial infections and the growing need for effective treatment options. Pneumonia is the most common respiratory infection in the US. According to Verywell Health Journal 2024 report, every year, ~1.5 million adults in the US are diagnosed with pneumonia; of which around 1 million are admitted to hospitals while 50,000 people die due to pneumonia or related complications. Amoxicillin and azithromycin are the most commonly used antibiotics prescribed in the US in outpatient settings for the treatment of bacterial infections. In addition, with ongoing advancements in pharmaceutical research and technology, the development of new antibiotics and antifungal agents has gained momentum, responding to the growing concerns about antibiotic resistance and the need for innovative therapies. Moreover, the growing awareness about the importance of antimicrobial stewardship programs has led to a more cautious approach to antibiotic prescription, prompting a shift toward targeted therapies and combination treatments. This is particularly evident in hospital settings, where the growing incidence of hospital-acquired infections necessitates the use of potent antimicrobials.

Key players are taking strategic initiatives such as product launches, product approvals, and collaborations, which are expected to support the market growth during the forecast period. For instance, in April 2024, the US Food and Drug Administration (FDA) approved Zevtera (ceftobiprole medocaril sodium for injection) for the treatment of adults suffering from Staphylococcus aureus bloodstream infections (SAB), including those with right-sided infective endocarditis and adults suffering from acute bacterial skin and skin structure infections (ABSSSI). Additionally, in March 2023, The US FDA approved REZZAYO (rezafungin for injection) for the treatment of candidemia and invasive candidiasis.

Technological Advancements in Product Development and Treatment Delivery Approaches

The pharmaceutical industry emphasizes incorporating intelligent technologies such as deep learning, artificial intelligence (AI), and machine learning in the development of new antibiotics. Researchers are working to establish tools and platforms for identifying new active compounds. Harnessing the capabilities of novel technologies in new antibiotic discoveries is expected to change the overall course of antibiotic and antimycotic development and approval processes.

Developing antibiotics for Gram-negative bacteria poses a significant challenge to researchers, and many drugs are still in the development phases. Limited permeability across the envelope of these bacteria due to nutrient-specific protein channels (porins) restricts the movement of non-essential molecules (including antibiotics) across membranes. Considering the difficulties around cell membrane permeability, researchers have developed a new Computational Antibiotic Screening Platform (CLASP) that helps identify potential drug molecules based on the analysis of porins. Advantages such as coarse grain (CG) resolution, advanced sampling techniques, and a parallel computing environment maximize the performance of CLASPs. The platform provides complete thermodynamic and kinetic results for a potential drug molecule under study in a few hours. It also helps understand or identify small molecule libraries that yield structure-property relationships to discover antibiotics with high permeability.

There is a rising inclination toward precision medicine approaches that involve adjusting antibiotic treatments based on patients' genetic profiles and resistance patterns that are common among large populations. Such a revolution would improve drugs' functionality while ensuring minimal adverse effects and curbing the development of resistance. Phage therapy has emerged as another novel approach that involves a potential combination of traditional microbial treatments with bacteriophages to target and destroy antibiotic-resistant pathogens. Promising recent advancements in gene-editing technologies, such as CRISPR, has the ability to further enhance the prospects of phage therapy. Thus, technological advancements in drug development and treatment delivery approaches are expected to bring new growth trends in the antibiotics and antimycotics market growth in the coming years.

Antibiotics and Antimycotics Market: Competitive Landscape and Key Developments

Pfizer Inc, Novartis AG, Sanofi SA, F. Hoffmann-La Roche Ltd, Merck & Co Inc, GSK Plc, Johnson & Johnson, Cipla Ltd, Bayer AG, AbbVie Inc, and Astellas Pharma Inc. are among the key companies operating in the antibiotics and antimycotics market.

The US Food and Drug Administration, National Institute of Health, United Nations International Children's Emergency Fund (UNICEF), World Health Organization (WHO), National Notifiable Diseases Surveillance System are among the primary and secondary sources referred to while preparing the antibiotics and antimycotics market report.

Table Of Contents

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights

3. Research Methodology

  • 3.1 Secondary Research
  • 3.2 Primary Research
    • 3.2.1 Hypothesis formulation:
    • 3.2.2 Macro-economic factor analysis:
    • 3.2.3 Developing base number:
    • 3.2.4 Data Triangulation:
    • 3.2.5 Country level data:

4. Antibiotics and Antimycotics Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis

5. Antibiotics and Antimycotics Market - Key Market Dynamics

  • 5.1 Antibiotics and Antimycotics Market - Key Market Dynamics
  • 5.2 Market Drivers:
    • 5.2.1 Increasing Prevalence of Infectious Diseases
    • 5.2.2 Growing Awareness About Fungal Infections
  • 5.3 Market Restraints
    • 5.3.1 Antimicrobial Resistance, Financial Barriers, and Extensive Regulatory Processes
  • 5.4 Market Opportunities
    • 5.4.1 Ongoing Funding and Research & Development Initiatives
  • 5.5 Future Trends
    • 5.5.1 Technological Advancements in Product Development and Treatment Delivery Approaches
  • 5.6 Impact of Drivers and Restraints:

6. Antibiotics and Antimycotics Market - Global Market Analysis

  • 6.1 Antibiotics and Antimycotics Market Revenue (US$ Million), 2021-2031
  • 6.2 Antibiotics and Antimycotics Market Forecast Analysis

7. Antibiotics and Antimycotics Market Analysis - by Drug Class

  • 7.1 Penicillin
    • 7.1.1 Overview
    • 7.1.2 Penicillin: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.2 Cephalosporines
    • 7.2.1 Overview
    • 7.2.2 Cephalosporines: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.3 Carbapenems
    • 7.3.1 Overview
    • 7.3.2 Carbapenems: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.4 Macrolides
    • 7.4.1 Overview
    • 7.4.2 Macrolides: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.5 Aminoglycosides
    • 7.5.1 Overview
    • 7.5.2 Aminoglycosides: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.6 Quinolones
    • 7.6.1 Overview
    • 7.6.2 Quinolones: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.7 Sulfonamides
    • 7.7.1 Overview
    • 7.7.2 Sulfonamides: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.8 Tetracyclines
    • 7.8.1 Overview
    • 7.8.2 Tetracyclines: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.9 Azoles
    • 7.9.1 Overview
    • 7.9.2 Azoles: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.10 Others
    • 7.10.1 Overview
    • 7.10.2 Others: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)

8. Antibiotics and Antimycotics Market Analysis - by Indication

  • 8.1 Skin Infections
    • 8.1.1 Overview
    • 8.1.2 Skin Infections: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.2 Respiratory Infections
    • 8.2.1 Overview
    • 8.2.2 Respiratory Infections: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.3 Urinary Tract Infections (UTI)
    • 8.3.1 Overview
    • 8.3.2 Urinary Tract Infections (UTI): Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.4 Septicemia
    • 8.4.1 Overview
    • 8.4.2 Septicemia: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.5 Ear Infections
    • 8.5.1 Overview
    • 8.5.2 Ear Infections: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.6 Gastrointestinal Infections
    • 8.6.1 Overview
    • 8.6.2 Gastrointestinal Infections: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.7 Others
    • 8.7.1 Overview
    • 8.7.2 Others: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)

9. Antibiotics and Antimycotics Market Analysis - by Route Of Administration

  • 9.1 Oral
    • 9.1.1 Overview
    • 9.1.2 Oral: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
  • 9.2 Topical
    • 9.2.1 Overview
    • 9.2.2 Topical: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
  • 9.3 Others
    • 9.3.1 Overview
    • 9.3.2 Others: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)

10. Antibiotics and Antimycotics Market Analysis - by Distribution Channel

  • 10.1 Hospital Pharmacies
    • 10.1.1 Overview
    • 10.1.2 Hospital Pharmacies: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
  • 10.2 Retail Pharmacies
    • 10.2.1 Overview
    • 10.2.2 Retail Pharmacies: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
  • 10.3 Online Pharmacies
    • 10.3.1 Overview
    • 10.3.2 Online Pharmacies: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)

11. Antibiotics and Antimycotics Market - Geographical Analysis

  • 11.1 North America
    • 11.1.1 North America Antibiotics and Antimycotics Market Overview
    • 11.1.2 North America: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
      • 11.1.2.1 North America: Antibiotics and Antimycotics Market - Revenue and Forecast Analysis - by Drug Class
      • 11.1.2.2 North America: Antibiotics and Antimycotics Market - Revenue and Forecast Analysis - by Indication
      • 11.1.2.3 North America: Antibiotics and Antimycotics Market - Revenue and Forecast Analysis - by Route Of Administration
      • 11.1.2.4 North America: Antibiotics and Antimycotics Market - Revenue and Forecast Analysis - by Distribution Channel
    • 11.1.3 North America: Antibiotics and Antimycotics Market - Revenue and Forecast Analysis - by Country
      • 11.1.3.1 United States: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.1.3.1.1 United States: Antibiotics and Antimycotics Market Breakdown, by Drug Class
        • 11.1.3.1.2 United States: Antibiotics and Antimycotics Market Breakdown, by Indication
        • 11.1.3.1.3 United States: Antibiotics and Antimycotics Market Breakdown, by Route Of Administration
        • 11.1.3.1.4 United States: Antibiotics and Antimycotics Market Breakdown, by Distribution Channel
      • 11.1.3.2 Canada: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.1.3.2.1 Canada: Antibiotics and Antimycotics Market Breakdown, by Drug Class
        • 11.1.3.2.2 Canada: Antibiotics and Antimycotics Market Breakdown, by Indication
        • 11.1.3.2.3 Canada: Antibiotics and Antimycotics Market Breakdown, by Route Of Administration
        • 11.1.3.2.4 Canada: Antibiotics and Antimycotics Market Breakdown, by Distribution Channel
      • 11.1.3.3 Mexico: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.1.3.3.1 Mexico: Antibiotics and Antimycotics Market Breakdown, by Drug Class
        • 11.1.3.3.2 Mexico: Antibiotics and Antimycotics Market Breakdown, by Indication
        • 11.1.3.3.3 Mexico: Antibiotics and Antimycotics Market Breakdown, by Route Of Administration
        • 11.1.3.3.4 Mexico: Antibiotics and Antimycotics Market Breakdown, by Distribution Channel
  • 11.2 Europe
    • 11.2.1 Europe Antibiotics and Antimycotics Market Overview
    • 11.2.2 Europe: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
      • 11.2.2.1 Europe: Antibiotics and Antimycotics Market - Revenue and Forecast Analysis - by Drug Class
      • 11.2.2.2 Europe: Antibiotics and Antimycotics Market - Revenue and Forecast Analysis - by Indication
      • 11.2.2.3 Europe: Antibiotics and Antimycotics Market - Revenue and Forecast Analysis - by Route Of Administration
      • 11.2.2.4 Europe: Antibiotics and Antimycotics Market - Revenue and Forecast Analysis - by Distribution Channel
    • 11.2.3 Europe: Antibiotics and Antimycotics Market - Revenue and Forecast Analysis - by Country
      • 11.2.3.1 Germany: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.2.3.1.1 Germany: Antibiotics and Antimycotics Market Breakdown, by Drug Class
        • 11.2.3.1.2 Germany: Antibiotics and Antimycotics Market Breakdown, by Indication
        • 11.2.3.1.3 Germany: Antibiotics and Antimycotics Market Breakdown, by Route Of Administration
        • 11.2.3.1.4 Germany: Antibiotics and Antimycotics Market Breakdown, by Distribution Channel
      • 11.2.3.2 France: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.2.3.2.1 France: Antibiotics and Antimycotics Market Breakdown, by Drug Class
        • 11.2.3.2.2 France: Antibiotics and Antimycotics Market Breakdown, by Indication
        • 11.2.3.2.3 France: Antibiotics and Antimycotics Market Breakdown, by Route Of Administration
        • 11.2.3.2.4 France: Antibiotics and Antimycotics Market Breakdown, by Distribution Channel
      • 11.2.3.3 Spain: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.2.3.3.1 Spain: Antibiotics and Antimycotics Market Breakdown, by Drug Class
        • 11.2.3.3.2 Spain: Antibiotics and Antimycotics Market Breakdown, by Indication
        • 11.2.3.3.3 Spain: Antibiotics and Antimycotics Market Breakdown, by Route Of Administration
        • 11.2.3.3.4 Spain: Antibiotics and Antimycotics Market Breakdown, by Distribution Channel
      • 11.2.3.4 Italy: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.2.3.4.1 Italy: Antibiotics and Antimycotics Market Breakdown, by Drug Class
        • 11.2.3.4.2 Italy: Antibiotics and Antimycotics Market Breakdown, by Indication
        • 11.2.3.4.3 Italy: Antibiotics and Antimycotics Market Breakdown, by Route Of Administration
        • 11.2.3.4.4 Italy: Antibiotics and Antimycotics Market Breakdown, by Distribution Channel
      • 11.2.3.5 United Kingdom: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.2.3.5.1 United Kingdom: Antibiotics and Antimycotics Market Breakdown, by Drug Class
        • 11.2.3.5.2 United Kingdom: Antibiotics and Antimycotics Market Breakdown, by Indication
        • 11.2.3.5.3 United Kingdom: Antibiotics and Antimycotics Market Breakdown, by Route Of Administration
        • 11.2.3.5.4 United Kingdom: Antibiotics and Antimycotics Market Breakdown, by Distribution Channel
      • 11.2.3.6 Rest of Europe: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.2.3.6.1 Rest of Europe: Antibiotics and Antimycotics Market Breakdown, by Drug Class
        • 11.2.3.6.2 Rest of Europe: Antibiotics and Antimycotics Market Breakdown, by Indication
        • 11.2.3.6.3 Rest of Europe: Antibiotics and Antimycotics Market Breakdown, by Route Of Administration
        • 11.2.3.6.4 Rest of Europe: Antibiotics and Antimycotics Market Breakdown, by Distribution Channel
  • 11.3 Asia Pacific
    • 11.3.1 Asia Pacific Antibiotics and Antimycotics Market Overview
    • 11.3.2 Asia Pacific: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
      • 11.3.2.1 Asia Pacific: Antibiotics and Antimycotics Market - Revenue and Forecast Analysis - by Drug Class
      • 11.3.2.2 Asia Pacific: Antibiotics and Antimycotics Market - Revenue and Forecast Analysis - by Indication
      • 11.3.2.3 Asia Pacific: Antibiotics and Antimycotics Market - Revenue and Forecast Analysis - by Route Of Administration
      • 11.3.2.4 Asia Pacific: Antibiotics and Antimycotics Market - Revenue and Forecast Analysis - by Distribution Channel
    • 11.3.3 Asia Pacific: Antibiotics and Antimycotics Market - Revenue and Forecast Analysis - by Country
      • 11.3.3.1 China: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.3.3.1.1 China: Antibiotics and Antimycotics Market Breakdown, by Drug Class
        • 11.3.3.1.2 China: Antibiotics and Antimycotics Market Breakdown, by Indication
        • 11.3.3.1.3 China: Antibiotics and Antimycotics Market Breakdown, by Route Of Administration
        • 11.3.3.1.4 China: Antibiotics and Antimycotics Market Breakdown, by Distribution Channel
      • 11.3.3.2 Japan: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.3.3.2.1 Japan: Antibiotics and Antimycotics Market Breakdown, by Drug Class
        • 11.3.3.2.2 Japan: Antibiotics and Antimycotics Market Breakdown, by Indication
        • 11.3.3.2.3 Japan: Antibiotics and Antimycotics Market Breakdown, by Route Of Administration
        • 11.3.3.2.4 Japan: Antibiotics and Antimycotics Market Breakdown, by Distribution Channel
      • 11.3.3.3 India: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.3.3.3.1 India: Antibiotics and Antimycotics Market Breakdown, by Drug Class
        • 11.3.3.3.2 India: Antibiotics and Antimycotics Market Breakdown, by Indication
        • 11.3.3.3.3 India: Antibiotics and Antimycotics Market Breakdown, by Route Of Administration
        • 11.3.3.3.4 India: Antibiotics and Antimycotics Market Breakdown, by Distribution Channel
      • 11.3.3.4 Australia: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.3.3.4.1 Australia: Antibiotics and Antimycotics Market Breakdown, by Drug Class
        • 11.3.3.4.2 Australia: Antibiotics and Antimycotics Market Breakdown, by Indication
        • 11.3.3.4.3 Australia: Antibiotics and Antimycotics Market Breakdown, by Route Of Administration
        • 11.3.3.4.4 Australia: Antibiotics and Antimycotics Market Breakdown, by Distribution Channel
      • 11.3.3.5 South Korea: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.3.3.5.1 South Korea: Antibiotics and Antimycotics Market Breakdown, by Drug Class
        • 11.3.3.5.2 South Korea: Antibiotics and Antimycotics Market Breakdown, by Indication
        • 11.3.3.5.3 South Korea: Antibiotics and Antimycotics Market Breakdown, by Route Of Administration
        • 11.3.3.5.4 South Korea: Antibiotics and Antimycotics Market Breakdown, by Distribution Channel
      • 11.3.3.6 Rest of APAC: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.3.3.6.1 Rest of APAC: Antibiotics and Antimycotics Market Breakdown, by Drug Class
        • 11.3.3.6.2 Rest of APAC: Antibiotics and Antimycotics Market Breakdown, by Indication
        • 11.3.3.6.3 Rest of APAC: Antibiotics and Antimycotics Market Breakdown, by Route Of Administration
        • 11.3.3.6.4 Rest of APAC: Antibiotics and Antimycotics Market Breakdown, by Distribution Channel
  • 11.4 Middle East and Africa
    • 11.4.1 Middle East and Africa Antibiotics and Antimycotics Market Overview
    • 11.4.2 Middle East and Africa: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
      • 11.4.2.1 Middle East and Africa: Antibiotics and Antimycotics Market - Revenue and Forecast Analysis - by Drug Class
      • 11.4.2.2 Middle East and Africa: Antibiotics and Antimycotics Market - Revenue and Forecast Analysis - by Indication
      • 11.4.2.3 Middle East and Africa: Antibiotics and Antimycotics Market - Revenue and Forecast Analysis - by Route Of Administration
      • 11.4.2.4 Middle East and Africa: Antibiotics and Antimycotics Market - Revenue and Forecast Analysis - by Distribution Channel
    • 11.4.3 Middle East and Africa: Antibiotics and Antimycotics Market - Revenue and Forecast Analysis - by Country
      • 11.4.3.1 Saudi Arabia: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.4.3.1.1 Saudi Arabia: Antibiotics and Antimycotics Market Breakdown, by Drug Class
        • 11.4.3.1.2 Saudi Arabia: Antibiotics and Antimycotics Market Breakdown, by Indication
        • 11.4.3.1.3 Saudi Arabia: Antibiotics and Antimycotics Market Breakdown, by Route Of Administration
        • 11.4.3.1.4 Saudi Arabia: Antibiotics and Antimycotics Market Breakdown, by Distribution Channel
      • 11.4.3.2 South Africa: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.4.3.2.1 South Africa: Antibiotics and Antimycotics Market Breakdown, by Drug Class
        • 11.4.3.2.2 South Africa: Antibiotics and Antimycotics Market Breakdown, by Indication
        • 11.4.3.2.3 South Africa: Antibiotics and Antimycotics Market Breakdown, by Route Of Administration
        • 11.4.3.2.4 South Africa: Antibiotics and Antimycotics Market Breakdown, by Distribution Channel
      • 11.4.3.3 United Arab Emirates: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.4.3.3.1 United Arab Emirates: Antibiotics and Antimycotics Market Breakdown, by Drug Class
        • 11.4.3.3.2 United Arab Emirates: Antibiotics and Antimycotics Market Breakdown, by Indication
        • 11.4.3.3.3 United Arab Emirates: Antibiotics and Antimycotics Market Breakdown, by Route Of Administration
        • 11.4.3.3.4 United Arab Emirates: Antibiotics and Antimycotics Market Breakdown, by Distribution Channel
      • 11.4.3.4 Rest of Middle East and Africa: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.4.3.4.1 Rest of Middle East and Africa: Antibiotics and Antimycotics Market Breakdown, by Drug Class
        • 11.4.3.4.2 Rest of Middle East and Africa: Antibiotics and Antimycotics Market Breakdown, by Indication
        • 11.4.3.4.3 Rest of Middle East and Africa: Antibiotics and Antimycotics Market Breakdown, by Route Of Administration
        • 11.4.3.4.4 Rest of Middle East and Africa: Antibiotics and Antimycotics Market Breakdown, by Distribution Channel
  • 11.5 South and Central America
    • 11.5.1 South and Central America Antibiotics and Antimycotics Market Overview
    • 11.5.2 South and Central America: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
      • 11.5.2.1 South and Central America: Antibiotics and Antimycotics Market - Revenue and Forecast Analysis - by Drug Class
      • 11.5.2.2 South and Central America: Antibiotics and Antimycotics Market - Revenue and Forecast Analysis - by Indication
      • 11.5.2.3 South and Central America: Antibiotics and Antimycotics Market - Revenue and Forecast Analysis - by Route Of Administration
      • 11.5.2.4 South and Central America: Antibiotics and Antimycotics Market - Revenue and Forecast Analysis - by Distribution Channel
    • 11.5.3 South and Central America: Antibiotics and Antimycotics Market - Revenue and Forecast Analysis - by Country
      • 11.5.3.1 Brazil: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.5.3.1.1 Brazil: Antibiotics and Antimycotics Market Breakdown, by Drug Class
        • 11.5.3.1.2 Brazil: Antibiotics and Antimycotics Market Breakdown, by Indication
        • 11.5.3.1.3 Brazil: Antibiotics and Antimycotics Market Breakdown, by Route Of Administration
        • 11.5.3.1.4 Brazil: Antibiotics and Antimycotics Market Breakdown, by Distribution Channel
      • 11.5.3.2 Argentina: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.5.3.2.1 Argentina: Antibiotics and Antimycotics Market Breakdown, by Drug Class
        • 11.5.3.2.2 Argentina: Antibiotics and Antimycotics Market Breakdown, by Indication
        • 11.5.3.2.3 Argentina: Antibiotics and Antimycotics Market Breakdown, by Route Of Administration
        • 11.5.3.2.4 Argentina: Antibiotics and Antimycotics Market Breakdown, by Distribution Channel
      • 11.5.3.3 Rest of South and Central America: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.5.3.3.1 Rest of South and Central America: Antibiotics and Antimycotics Market Breakdown, by Drug Class
        • 11.5.3.3.2 Rest of South and Central America: Antibiotics and Antimycotics Market Breakdown, by Indication
        • 11.5.3.3.3 Rest of South and Central America: Antibiotics and Antimycotics Market Breakdown, by Route Of Administration
        • 11.5.3.3.4 Rest of South and Central America: Antibiotics and Antimycotics Market Breakdown, by Distribution Channel

12. Antibiotics and Antimycotics Market - Industry Landscape

  • 12.1 Overview
  • 12.2 Growth Strategies in Antibiotics and Antimycotics Market
  • 12.3 Organic Growth Strategies
    • 12.3.1 Overview
  • 12.4 Inorganic Growth Strategies
    • 12.4.1 Overview

13. Company Profiles

  • 13.1 Pfizer Inc
    • 13.1.1 Key Facts
    • 13.1.2 Business Description
    • 13.1.3 Products and Services
    • 13.1.4 Financial Overview
    • 13.1.5 SWOT Analysis
    • 13.1.6 Key Developments
  • 13.2 Novartis AG
    • 13.2.1 Key Facts
    • 13.2.2 Business Description
    • 13.2.3 Products and Services
    • 13.2.4 Financial Overview
    • 13.2.5 SWOT Analysis
    • 13.2.6 Key Developments
  • 13.3 Sanofi SA
    • 13.3.1 Key Facts
    • 13.3.2 Business Description
    • 13.3.3 Products and Services
    • 13.3.4 Financial Overview
    • 13.3.5 SWOT Analysis
    • 13.3.6 Key Developments
  • 13.4 F. Hoffmann-La Roche Ltd
    • 13.4.1 Key Facts
    • 13.4.2 Business Description
    • 13.4.3 Products and Services
    • 13.4.4 Financial Overview
    • 13.4.5 SWOT Analysis
    • 13.4.6 Key Developments
  • 13.5 Merck & Co Inc
    • 13.5.1 Key Facts
    • 13.5.2 Business Description
    • 13.5.3 Products and Services
    • 13.5.4 Financial Overview
    • 13.5.5 SWOT Analysis
    • 13.5.6 Key Developments
  • 13.6 GSK Plc
    • 13.6.1 Key Facts
    • 13.6.2 Business Description
    • 13.6.3 Products and Services
    • 13.6.4 Financial Overview
    • 13.6.5 SWOT Analysis
    • 13.6.6 Key Developments
  • 13.7 Johnson & Johnson
    • 13.7.1 Key Facts
    • 13.7.2 Business Description
    • 13.7.3 Products and Services
    • 13.7.4 Financial Overview
    • 13.7.5 SWOT Analysis
    • 13.7.6 Key Developments
  • 13.8 Cipla Ltd
    • 13.8.1 Key Facts
    • 13.8.2 Business Description
    • 13.8.3 Products and Services
    • 13.8.4 Financial Overview
    • 13.8.5 SWOT Analysis
    • 13.8.6 Key Developments
  • 13.9 Bayer AG
    • 13.9.1 Key Facts
    • 13.9.2 Business Description
    • 13.9.3 Products and Services
    • 13.9.4 Financial Overview
    • 13.9.5 SWOT Analysis
    • 13.9.6 Key Developments
  • 13.10 AbbVie Inc
    • 13.10.1 Key Facts
    • 13.10.2 Business Description
    • 13.10.3 Products and Services
    • 13.10.4 Financial Overview
    • 13.10.5 SWOT Analysis
    • 13.10.6 Key Developments
  • 13.11 Astellas Pharma Inc
    • 13.11.1 Key Facts
    • 13.11.2 Business Description
    • 13.11.3 Products and Services
    • 13.11.4 Financial Overview
    • 13.11.5 SWOT Analysis
    • 13.11.6 Key Developments

14. Appendix

  • 14.1 About The Insight Partners
  • 14.2 Glossary of Terms

List Of Tables

  • Table 1. Antibiotics and Antimycotics Market Segmentation
  • Table 2. North America: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 3. North America: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
  • Table 4. North America: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Route Of Administration
  • Table 5. North America: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 6. United States: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 7. United States: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
  • Table 8. United States: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Route Of Administration
  • Table 9. United States: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 10. Canada: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 11. Canada: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
  • Table 12. Canada: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Route Of Administration
  • Table 13. Canada: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 14. Mexico: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 15. Mexico: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
  • Table 16. Mexico: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Route Of Administration
  • Table 17. Mexico: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 18. Europe: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 19. Europe: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
  • Table 20. Europe: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Route Of Administration
  • Table 21. Europe: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 22. Germany: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 23. Germany: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
  • Table 24. Germany: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Route Of Administration
  • Table 25. Germany: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 26. France: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 27. France: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
  • Table 28. France: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Route Of Administration
  • Table 29. France: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 30. Spain: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 31. Spain: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
  • Table 32. Spain: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Route Of Administration
  • Table 33. Spain: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 34. Italy: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 35. Italy: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
  • Table 36. Italy: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Route Of Administration
  • Table 37. Italy: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 38. United Kingdom: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 39. United Kingdom: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
  • Table 40. United Kingdom: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Route Of Administration
  • Table 41. United Kingdom: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 42. Rest of Europe: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 43. Rest of Europe: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
  • Table 44. Rest of Europe: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Route Of Administration
  • Table 45. Rest of Europe: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 46. Asia Pacific: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 47. Asia Pacific: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
  • Table 48. Asia Pacific: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Route Of Administration
  • Table 49. Asia Pacific: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 50. China: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 51. China: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
  • Table 52. China: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Route Of Administration
  • Table 53. China: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 54. Japan: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 55. Japan: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
  • Table 56. Japan: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Route Of Administration
  • Table 57. Japan: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 58. India: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 59. India: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
  • Table 60. India: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Route Of Administration
  • Table 61. India: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 62. Australia: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 63. Australia: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
  • Table 64. Australia: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Route Of Administration
  • Table 65. Australia: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 66. South Korea: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 67. South Korea: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
  • Table 68. South Korea: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Route Of Administration
  • Table 69. South Korea: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 70. Rest of APAC: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 71. Rest of APAC: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
  • Table 72. Rest of APAC: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Route Of Administration
  • Table 73. Rest of APAC: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 74. Middle East and Africa: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 75. Middle East and Africa: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
  • Table 76. Middle East and Africa: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Route Of Administration
  • Table 77. Middle East and Africa: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 78. Saudi Arabia: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 79. Saudi Arabia: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
  • Table 80. Saudi Arabia: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Route Of Administration
  • Table 81. Saudi Arabia: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 82. South Africa: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 83. South Africa: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
  • Table 84. South Africa: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Route Of Administration
  • Table 85. South Africa: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 86. United Arab Emirates: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 87. United Arab Emirates: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
  • Table 88. United Arab Emirates: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Route Of Administration
  • Table 89. United Arab Emirates: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 90. Rest of Middle East and Africa: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 91. Rest of Middle East and Africa: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million) - by Indication
  • Table 92. Rest of Middle East and Africa: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Route Of Administration
  • Table 93. Rest of Middle East and Africa: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 94. South and Central America: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 95. South and Central America: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
  • Table 96. South and Central America: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Route Of Administration
  • Table 97. South and Central America: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 98. Brazil: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 99. Brazil: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
  • Table 100. Brazil: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Route Of Administration
  • Table 101. Brazil: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 102. Argentina: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 103. Argentina: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
  • Table 104. Argentina: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Route Of Administration
  • Table 105. Argentina: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 106. Rest of South and Central America: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 107. Rest of South and Central America: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million) - by Indication
  • Table 108. Rest of South and Central America: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Route Of Administration
  • Table 109. Rest of South and Central America: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 110. Recent Organic Growth Strategies in Antibiotics and Antimycotics Market
  • Table 111. Recent Inorganic Growth Strategies in the Antibiotics and Antimycotics Market
  • Table 112. Glossary of Terms, Antibiotics and Antimycotics Market

List Of Figures

  • Figure 1. Antibiotics and Antimycotics Market Segmentation, by Geography
  • Figure 2. PEST Analysis
  • Figure 3. Impact Analysis of Drivers and Restraints
  • Figure 4. Antibiotics and Antimycotics Market Revenue (US$ Million), 2021-2031
  • Figure 5. Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 6. Antibiotics and Antimycotics Market Share (%) - by Drug Class (2023 and 2031)
  • Figure 7. Penicillin: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 8. Cephalosporines: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 9. Carbapenems: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 10. Macrolides: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 11. Aminoglycosides: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 12. Quinolones: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 13. Sulfonamides: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 14. Tetracyclines: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 15. Azoles: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 16. Others: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 17. Antibiotics and Antimycotics Market Share (%) - by Indication (2023 and 2031)
  • Figure 18. Skin Infections: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 19. Respiratory Infections: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 20. Urinary Tract Infections (UTI): Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 21. Septicemia: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 22. Ear Infections: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 23. Gastrointestinal Infections: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 24. Others: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 25. Antibiotics and Antimycotics Market Share (%) - by Route Of Administration (2023 and 2031)
  • Figure 26. Oral: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 27. Topical: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 28. Others: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 29. Antibiotics and Antimycotics Market Share (%) - by Distribution Channel (2023 and 2031)
  • Figure 30. Hospital Pharmacies: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 31. Retail Pharmacies: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 32. Online Pharmacies: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 33. North America: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 34. North America: Antibiotics and Antimycotics Market Breakdown, by Key Countries, 2023 and 2031 (%)
  • Figure 35. United States: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 36. Canada: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 37. Mexico: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 38. Europe: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 39. Europe: Antibiotics and Antimycotics Market Breakdown, by Key Countries, 2023 and 2031 (%)
  • Figure 40. Germany: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 41. France: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 42. Spain: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 43. Italy: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 44. United Kingdom: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 45. Rest of Europe: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 46. Asia Pacific: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 47. Asia Pacific: Antibiotics and Antimycotics Market Breakdown, by Key Countries, 2023 and 2031 (%)
  • Figure 48. China: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 49. Japan: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 50. India: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 51. Australia: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 52. South Korea: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 53. Rest of APAC: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 54. Middle East and Africa: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 55. Middle East and Africa: Antibiotics and Antimycotics Market Breakdown, by Key Countries, 2023 and 2031 (%)
  • Figure 56. Saudi Arabia: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 57. South Africa: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 58. United Arab Emirates: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 59. Rest of Middle East and Africa: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 60. South and Central America: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 61. South and Central America: Antibiotics and Antimycotics Market Breakdown, by Key Countries, 2023 and 2031 (%)
  • Figure 62. Brazil: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 63. Argentina: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 64. Rest of South and Central America: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 65. Growth Strategies in Antibiotics and Antimycotics Market